Stride downgraded to Equal Weight from Overweight at Morgan Stanley

Morgan Stanley analyst Greg Parrish downgraded Stride to Equal Weight from Overweight with an unchanged price target of $46. The stock has outperformed the market by 36% year-to-date, and at this level the stock offers a more balanced risk/reward, the analyst tells investors in a research note. The firm is positive on Stride’s growth potential, but believes enrollment overhang risk is now appropriately priced into the valuation.